500,000 Shares in Drugs Made In America Acquisition II Corp. $DMII Acquired by Sculptor Capital LP

Sculptor Capital LP acquired a new position in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 500,000 shares of the company’s stock, valued at approximately $4,950,000.

A number of other large investors also recently added to or reduced their stakes in the company. Glazer Capital LLC acquired a new position in Drugs Made In America Acquisition II during the fourth quarter worth $23,264,000. First Trust Capital Management L.P. acquired a new position in Drugs Made In America Acquisition II during the fourth quarter worth $20,474,000. Hudson Bay Capital Management LP acquired a new position in Drugs Made In America Acquisition II during the fourth quarter worth $19,493,000. Wolverine Asset Management LLC acquired a new position in Drugs Made In America Acquisition II during the fourth quarter worth $10,521,000. Finally, Picton Mahoney Asset Management acquired a new position in Drugs Made In America Acquisition II during the fourth quarter worth $8,662,000.

Wall Street Analysts Forecast Growth

DMII has been the topic of a number of research reports. Weiss Ratings upgraded Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday. Wall Street Zen upgraded Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Drugs Made In America Acquisition II Stock Performance

NASDAQ:DMII opened at $10.09 on Tuesday. The stock’s fifty day moving average price is $10.03. Drugs Made In America Acquisition II Corp. has a 52 week low of $9.86 and a 52 week high of $10.09.

Drugs Made In America Acquisition II Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.